Use of Insulin Glargine During the First Weeks of Pregnancy in Five Type 1 Diabetic Women
- Graziano Di Cianni, MD,
- Laura Volpe, MD,
- Cristina Lencioni, MD,
- Kyriazoula Chatzianagnostou, MD,
- Ilaria Cuccuru, MD,
- Alessandra Ghio, MD,
- Luca Benzi, MD and
- Stefano Del Prato, MD
- From the Department of Endocrinology and Metabolism, Section of Diabetes, University of Pisa, Pisa, Italy
- Address correspondence to Dr. Graziano Di Cianni, Department of Endocrinology and Metabolism, Section of Diabetes and Metabolic Diseases, Ospedale di Cisanello, Via Paradisa, 2, I-56126 Pisa, Italy. E-mail: dicianni{at}immr.med.unipi.it
The long-acting analog glargine is a new insulin with 24-h persistence. This peculiar peakless action profile accounts for significant risk reduction for nocturnal hypoglycemia and a more stable daily plasma glucose profile (1,2). Only a few reports have described the use of insulin glargine during human pregnancy, so its use is not recommended at present. Animal studies have addressed the safety and efficacy of glargine during pregnancy, showing no direct effect on reproduction and embryo-fetal development (3). Recently, Devlin et al. (4) and Holstein et al. (5) reported the use of insulin glargine in two type 1 diabetic women; both cases were free of any pregnancy complications and …
In this Issue
April 2005, 28(4)
Use of Insulin Glargine During the First Weeks of Pregnancy in Five Type 1 Diabetic Women
